The short version of peptide research fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-29 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
== Research and career == In 1975, Theo Wallimann completed his Ph.D. Dissertation on “M-line-bound Creatine Kinase and Myofibrillar Structure” in the laboratory of Prof. Hans M. Eppenberger at the Institute of Cell Biology at ETH Zurich with distinction and received the ETH prize and medal. From 1975 - 1981, Wallimann worked as a post-doctoral research associate with Andrew G. Szent-Györgyi , at the Biology Department of Brandeis University on the subject of "Myosin-linked calcium regulation of muscle contraction". After rejoining the Biology Dept of the ETH-Zurich in 1981, Wallimann became a Lecturer in 1984 with his Habilitation on: "Localization and function of M-line-bound creatine kinase: M-band model and Phospho-Creatine Shuttle"). In 1994, Wallimann was awarded the title of Professor and in the next two years he became Head and Deputy Head of the Institute of Cell Biology. Wallimann resigned from his post in June 2008 and is now Emeritus and member of the ETH Alumni organisation. In 2005, Wallimann was awarded with the Alfred-Vogt-Prize in 2005 and in 2023, 2024 and 2025 he received the Research.com Recognition Leader Award for Biology and Biochemistry in Switzerland. In 2025, Theo Wallimann has been honored by the International Society of Sports Nutrition with a “Life-time Achievement Award” for his research on the «Creatine Kinase System and Creatine», at the Internatl. Congress on «Creatine for Health», held during March 12th-16th 2025 in Munich, Germany: https://creatineforhealth.com/creatine-conference-2025/
Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) Psilocin (4-hydroxy-N,N-dimethyltryptamine) Baeocystin (4-phosphoryloxy-N-methyltryptamine) Norbaeocystin (4-phosphoryloxytryptamine) Aeruginascin (N,N,N-trimethyl-4-phosphoryloxytryptamine) The potential psychoactivity of other compounds other than psilocybin and psilocin has been speculated but not confirmed. The concentrations of psilocin and psilocybin, as determined by high-performance liquid chromatography, are in the range of 0.14–0.42% (wet weight) and 0.37–1.30% (dry weight) in the whole mushroom 0.17–0.78% (wet weight) and 0.44–1.35% (dry weight) in the cap, and 0.09%–0.30% (wet weight) and 0.05–1.27% (dry weight) in the stem, respectively. For quickly and practically measuring the psychoactive contents of most healthy Psilocybe cubensis varieties, it can generally be assumed that there is approximately 15 mg (± 5 mg) of psilocybin per gram of dried mushroom. Furthermore, due to factors such as age and storage method, the psilocybin and psilocin content of a given sample of mushrooms will vary. Individual body composition, brain chemistry and psychological predisposition play a significant role in determining appropriate doses. For a modest psychedelic effect, a minimum of one gram of dried Psilocybe cubensis mushrooms is ingested orally, 0.25–1 gram is usually sufficient to produce a mild effect, 1–2.5 grams usually provides a moderate effect and 2.5 grams and higher usually produces strong effects.
=== Polymers === In polymer chemistry, MALDI can be used to determine the molar mass distribution. Polymers with polydispersity greater than 1.2 are difficult to characterize with MALDI due to the signal intensity discrimination against higher mass oligomers. A good matrix for polymers is dithranol or AgTFA. The sample must first be mixed with dithranol and the AgTFA added afterwards; otherwise the sample will precipitate out of solution.
Sources: en.wikipedia.org
=== Sexual role reversal === It is common among Lepidoptera for females to use pheromones to attract males for mating. In T. ni, both males and females produce pheromones capable of attracting the opposite sex. This has been cited as an example of sexual role reversal.
44 (9): 1829. doi:10.1016/0009-2509(89)85125-5. M. König (2008). Herstellung und Charakterisierung nanoporöser Monolithe auf Basis poröser Gläser mit optimierter geometrischer Form zur Anwendung in der Sensortechnik. Diplomarbeit, Halle.
Formylation refers to any chemical processes in which a compound is functionalized with a formyl group (-CH=O). In organic chemistry, the term is most commonly used with regard to aromatic compounds (for example, the conversion of benzene to benzaldehyde in the Gattermann–Koch reaction). In biochemistry, the reaction is catalysed by enzymes such as formyltransferases. Formylation generally involves the use of formylation agents, reagents that give rise to the CHO group. Among the many formylation reagents, particularly important are formic acid and carbon monoxide. A formylation reaction in organic chemistry refers to organic reactions in which an organic compound is functionalized with a formyl group (-CH=O). The reaction is a route to aldehydes (C-CH=O), formamides (N-CH=O), and formate esters (O-CH=O).
Sources: en.wikipedia.org
Clot-dissolving agents (tissue plasminogen activator) Maggot larval debridement Correction of the underlying plasma calcium and phosphorus abnormalities (lowering the Ca x P product below 55 mg2/dL2) Avoiding further local tissue trauma (including avoiding all subcutaneous injections, and all not-absolutely-necessary infusions and transfusions) Patients who have received kidney transplants also receive immunosuppression. Considering lowering the dose of or discontinuing the use of immunosuppressive drugs in people who have received kidney transplants and continue to have persistent or progressive calciphylactic skin lesions can contribute to an acceptable treatment of calciphylaxis. A group in 2013 reported plasma exchange effective and proposed a serum marker and perhaps a mechanistic mediator (calciprotein)
Humans express two distinct isozymes of IMPDH encoded by two distinct genes, IMPDH1 and IMPDH2. Both isozymes contain 514 residues, have an 84% similarity in peptide sequence, and have similar kinetic properties. Both isozymes are constitutively expressed in most tissues, but IMPDH1 is predominately expressed in the spleen, retina, and peripheral blood leukocytes. IMPDH1 is generally expressed constitutively at low levels, and IMPDH2 is generally upregulated in proliferating cells and neoplastic tissues. Homozygous IMPDH1 knockout mice demonstrate a mild retinopathy in which a slow, progressive form of retinal degeneration gradually weakens visual transduction, while homozygous IMPDH2 knockout mice display embryonic lethality.
==== Revolts of the era of the Spring of Nations ==== The planned national uprising failed to materialize because the authorities in the partitions found out about secret preparations. The Greater Poland uprising ended in a fiasco in early 1846. In the Kraków uprising of February 1846, patriotic action was combined with revolutionary demands, but the result was the incorporation of the Free City of Cracow into the Austrian Partition. The Austrian officials took advantage of peasant discontent and incited villagers against the noble-dominated insurgent units. This resulted in the Galician slaughter of 1846, a large-scale rebellion of serfs seeking relief from their post-feudal condition of mandatory labor as practiced in folwarks. The uprising freed many from bondage and hastened decisions that led to the abolition of Polish serfdom in the Austrian Empire in 1848. A new wave of Polish involvement in revolutionary movements soon took place in the partitions and in other parts of Europe in the context of the Spring of Nations revolutions of 1848 (e.g. Józef Bem's participation in the revolutions in Austria and Hungary). The 1848 German revolutions precipitated the Greater Poland uprising of 1848, in which peasants in the Prussian Partition, who were by then largely enfranchised, played a prominent role.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.